Astera Labs, Inc. $ALAB Shares Sold by F m Investments LLC

F m Investments LLC lessened its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 2.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 23,229 shares of the company’s stock after selling 488 shares during the period. F m Investments LLC’s holdings in Astera Labs were worth $2,100,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALAB. Oliver Lagore Vanvalin Investment Group acquired a new position in Astera Labs during the second quarter worth $29,000. Bernard Wealth Management Corp. purchased a new stake in shares of Astera Labs in the 2nd quarter valued at $36,000. Clearstead Trust LLC raised its holdings in shares of Astera Labs by 46,100.0% in the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after buying an additional 461 shares during the period. Advisors Asset Management Inc. lifted its stake in Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after acquiring an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after acquiring an additional 283 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Stock Up 2.1%

Shares of Astera Labs stock opened at $157.54 on Friday. Astera Labs, Inc. has a 52-week low of $47.13 and a 52-week high of $262.90. The company has a market capitalization of $26.61 billion, a P/E ratio of 141.92, a P/E/G ratio of 2.87 and a beta of 1.37. The company has a 50 day moving average of $175.95 and a 200 day moving average of $148.48.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $230.58 million for the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company’s quarterly revenue was up 103.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, research analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jitendra Mohan sold 90,459 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the transaction, the chief executive officer owned 2,080,418 shares in the company, valued at approximately $301,015,680.42. This represents a 4.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Philip Mazzara sold 4,620 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $668,467.80. Following the sale, the general counsel owned 147,040 shares of the company’s stock, valued at approximately $21,275,217.60. The trade was a 3.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 586,936 shares of company stock valued at $90,628,610 over the last 90 days. 12.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ALAB shares. Zacks Research lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Wall Street Zen cut shares of Astera Labs from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Needham & Company LLC upped their target price on shares of Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Barclays reissued an “equal weight” rating and issued a $155.00 price target on shares of Astera Labs in a research report on Monday, October 20th. Finally, Roth Capital boosted their price target on shares of Astera Labs from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.06.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.